9.23

7.33% 0.63

Delcath Systems Inc (DCTH)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Delcath Systems Inc stock is traded at $9.23, with a volume of 778.07K. It is up +7.33% in the last 24 hours and down -4.85% over the past month. Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Previous Close:

$8.60

Open:

$8.9

24h Volume:

778.07K

Relative Volume:

1.52

Market Cap:

$320.28M

Revenue:

$2.07M

Net Income/Loss:

$-47.68M

P/E Ratio:

-3.273

EPS:

-2.82

Net Cash Flow:

$-31.31M

1W Performance:

-9.60%

1M Performance:

-4.85%

6M Performance:

-16.85%

1Y Performance:

-32.97%

1-Day Range:

$8.87

$9.30

1-Week Range:

$8.485

$9.80

52-Week Range:

$8.12

$18.23

Delcath Systems Inc Stock (DCTH) Company Profile

Name

Delcath Systems Inc

Sector

Healthcare (1106)

Industry

Medical Devices (138)

Phone

(518) 743-8892

Address

566 QUEENSBURY AVENUE, QUEENSBURY, NY

Employee

Twitter

@delcathsystems

Next Earnings Date

2024-11-08

Latest SEC Filings

DCTH's Discussions on Twitter

Compare DCTH vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DCTH Delcath Systems Inc	9.23	298.42M	2.07M	-47.68M	-31.31M	-2.82
ABT Abbott Laboratories	113.10	197.42B	44.33B	6.50B	7.40B	3.717
SYK Stryker Corp	381.89	147.18B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	95.60	124.16B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	72.21	109.58B	20.08B	2.89B	3.66B	1.9391
EW Edwards Lifesciences Corp	85.22	49.49B	6.07B	1.06B	1.34B	1.8063

Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-28-24	Initiated	Craig Hallum	Buy
May-14-24	Initiated	Stephens	Overweight
Jul-26-22	Resumed	Canaccord Genuity	Buy
Dec-10-21	Initiated	H.C. Wainwright	Buy
Mar-09-21	Initiated	Canaccord Genuity	Buy
Jan-05-21	Initiated	BTIG Research	Buy
Jun-01-20	Initiated	Laidlaw	Buy

View All

Delcath Systems Inc Stock (DCTH) Latest News

Mar 04, 2026

Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology - Yahoo Finance

Mar 04, 2026

HC Wainwright Lowers Earnings Estimates for Delcath Systems - MarketBeat

Mar 04, 2026

Delcath announces publication of liver cancer treatment trial - Investing.com

Mar 04, 2026

Delcath announces publication of liver cancer treatment trial By Investing.com - Investing.com Canada

Mar 04, 2026

Mar 03, 2026

Delcath Highlights CHOPIN Phase 2 Results in Uveal Melanoma - TipRanks

Mar 03, 2026

Insider Buying: Gerard Michel Acquires Additional Shares of Delc - GuruFocus

Mar 03, 2026

CHOPIN uveal melanoma trial data in Lancet boosts Delcath (Nasdaq: DCTH) - Stock Titan

Mar 03, 2026

[Form 4] DELCATH SYSTEMS, INC. Insider Trading Activity - Stock Titan

Mar 03, 2026

Delcath Systems announces publication of Chopin clinical trial results in The Lancet Oncology - marketscreener.com

Mar 03, 2026

Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 03, 2026

Delcath Systems Announces Publication Of Chopin Clinical Trial Results In The Lancet Oncology - TradingView

Mar 03, 2026

Liver-directed therapy plus immunotherapy extends survival in uveal melanoma - Stock Titan

Mar 03, 2026

FY2029 EPS Forecast for Delcath Systems Decreased by Analyst - MarketBeat

Mar 03, 2026

Mar 02, 2026

Delcath: Fundamentals Intact, Despite Share Price Weakness (NASDAQ:DCTH) - Seeking Alpha

Mar 02, 2026

Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 02, 2026

Uveal Melanoma Treatment Market Set to Soar: Breakthrough - openPR.com

Mar 02, 2026

Mar 01, 2026

DCTH Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Mar 01, 2026

Precision Trading with Delcath Systems Inc. (DCTH) Risk Zones - Stock Traders Daily

Mar 01, 2026

Feb 28, 2026

Analysts Offer Insights on Healthcare Companies: Baxter International (BAX), Nautilus Biotechnolgy (NAUT) and Delcath Systems (DCTH) - The Globe and Mail

Feb 28, 2026

Delcath Systems (NASDAQ:DCTH) Lowered to Hold Rating by Wall Street Zen - MarketBeat

Feb 28, 2026

Feb 27, 2026

Craig-Hallum cuts Delcath Systems stock price target on revenue guide - Investing.com Canada

Feb 27, 2026